Blog
RSS FeedPosted by Michael Wonder on 04 May 2026
'Tearing her skin apart': Sydney family among thousands priced out of life-changing medication
3 May 2026 - Jade Hlucshniow was on the brink of selling her home to afford treatment for her daughter, ...
Posted by Michael Wonder on 04 May 2026
Korea covers Takeda’s Takhzyro, but most patients may still be left out: experts
26 March 2026 - Korea has granted reimbursement for Takeda’s hereditary angioedema drug Takhzyro (lanadelumab), but physicians say most patients ...
Posted by Michael Wonder on 04 May 2026
New first in class therapy for chronic graft versus host disease approved in Australia
3 May 2026 - Specialised Therapeutics is pleased to announce that Niktimvo (axatilimab) has been approved for use in Australia ...
Posted by Michael Wonder on 03 May 2026
Affordable treatment for Australians with colorectal cancer
3 May 2026 - Australians with stage 4 colorectal cancer are among those who will benefit from new drug listings ...
Posted by Michael Wonder on 03 May 2026
US pushes real time clinical trials to eliminate “dead time” in approvals
1 May 2026 - The US FDA is testing “real time clinical trials,” which it says will provide faster access ...
Posted by Michael Wonder on 03 May 2026
Apotex becomes the first Canadian‑based pharmaceutical company to receive Health Canada approval for a generic equivalent of Ozempic
1 May 2026 - Apotex today announced that Health Canada has approved Apo‑Semaglutide Injection, a generic equivalent of Ozempic (semaglutide injection). ...
Posted by Michael Wonder on 03 May 2026
Novartis receives Health Canada approval for Fabhalta oral treatment for adults with C3G
1 May 2026 - Novartis Pharmaceuticals Canada announced today that Health Canada has granted a Notice of Compliance for Fabhalta (iptacopan ...
Posted by Michael Wonder on 03 May 2026
Incyte announces FDA Approval of Jakafi XR (ruxolitinib) extended release tablets for the treatment of myelofibrosis, polycythemia vera and graft versus host disease
1 May 2026 - Jakafi XR will be available for pharmacy orders by 8 May 2026. ...
Posted by Michael Wonder on 02 May 2026
MHRA approves Linerixibat (Lynavoy) for the treatment of itch due to biliary tract disease
1 May 2026 - The MHRA has today approved Linerixibat (Lynavoy) for use to treat an itch in adults with primary biliary cholangitis. ...
Posted by Michael Wonder on 02 May 2026
Stelara paediatric Crohn’s disease FDA approval J&J statement
1 May 2026 - On 15 April 2026, the US FDA approved Stelara (ustekinumab) for the treatment of patients two ...
Posted by Michael Wonder on 02 May 2026
Arrowhead Pharmaceuticals receives TGA approval of Redemplo (plozasiran) in Australia, expanding global access for patients with familial chylomicronaemia syndrome
1 May 2026 - The approval in Australia is based on positive results from the Phase 3 PALISADE study where ...
Posted by Michael Wonder on 01 May 2026
Johnson & Johnson to offer four prescription medicines on TrumpRx website
24 April 2026 - Johnson & Johnson will start selling four of its medications on the Trump administration's TrumpRx website, ...
Posted by Michael Wonder on 01 May 2026
FDA approves vepdegestrant for ER positive, HER2 negative, ESR1 mutated advanced or metastatic breast cancer
1 May 2026 - Today, the FDA approved vepdegestrant (Veppanu, Arvinas), a heterobifunctional protein degrader, for adults with oestrogen receptor ...
Posted by Michael Wonder on 01 May 2026
Agenda for the May 2026 PBAC meeting
1 May 2026 - The agenda for the May 2026 PBAC meeting is now available. ...
Posted by Michael Wonder on 01 May 2026
New Zealand Pharmaceutical Schedule - 1 May 2026
1 May 2026 - The May 2026 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...